BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30899515)

  • 1. Elevated doublecortin-like kinase 1 serum levels revert to baseline after therapy in early stage esophageal adenocarcinoma.
    Christman EM; Chandrakesan P; Weygant N; Maple JT; Tierney WM; Vega KJ; Houchen CW
    Biomark Res; 2019; 7():5. PubMed ID: 30899515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DCLK1 is detectable in plasma of patients with Barrett's esophagus and esophageal adenocarcinoma.
    Whorton J; Sureban SM; May R; Qu D; Lightfoot SA; Madhoun M; Johnson M; Tierney WM; Maple JT; Vega KJ; Houchen CW
    Dig Dis Sci; 2015 Feb; 60(2):509-13. PubMed ID: 25283374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett's Esophagus.
    Shah AK; Hartel G; Brown I; Winterford C; Na R; Cao KL; Spicer BA; Dunstone MA; Phillips WA; Lord RV; Barbour AP; Watson DI; Joshi V; Whiteman DC; Hill MM
    Mol Cell Proteomics; 2018 Dec; 17(12):2324-2334. PubMed ID: 30097534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Radiofrequency Ablation vs. Endoscopic Surveillance for Barrett's Esophagus With Low-Grade Dysplasia: Meta-Analysis of Randomized Controlled Trials.
    Wang Y; Ma B; Yang S; Li W; Li P
    Front Oncol; 2022; 12():801940. PubMed ID: 35296005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum 25-Hydroxyvitamin D Levels and the Risk of Dysplasia and Esophageal Adenocarcinoma in Patients with Barrett's Esophagus.
    Thota PN; Kistangari G; Singh P; Cummings L; Hajifathalian K; Lopez R; Sanaka MR
    Dig Dis Sci; 2016 Jan; 61(1):247-54. PubMed ID: 26233550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
    Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
    Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming human papillomavirus infection and the esophageal transformation zone: prime time for total excision/ablative therapy?
    Rajendra S; Sharma P
    Dis Esophagus; 2019 Jul; 32(7):. PubMed ID: 31304554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
    Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety outcomes of multimodal endoscopic eradication therapy in Barrett's esophagus-related neoplasia: a systematic review and pooled analysis.
    Desai M; Saligram S; Gupta N; Vennalaganti P; Bansal A; Choudhary A; Vennelaganti S; He J; Titi M; Maselli R; Qumseya B; Olyaee M; Waxman I; Repici A; Hassan C; Sharma P
    Gastrointest Endosc; 2017 Mar; 85(3):482-495.e4. PubMed ID: 27670227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoscopic therapy of esophageal premalignancy and early malignancy.
    Nealis TB; Washington K; Keswani RN
    J Natl Compr Canc Netw; 2011 Aug; 9(8):890-9. PubMed ID: 21900219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidisciplinary treatment of T1a adenocarcinoma in Barrett's esophagus: contemporary comparison of endoscopic and surgical treatment in physiologically fit patients.
    Schmidt HM; Mohiuddin K; Bodnar AM; El Lakis M; Kaplan S; Irani S; Gan I; Ross A; Low DE
    Surg Endosc; 2016 Aug; 30(8):3391-401. PubMed ID: 26541725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma.
    Rizk NP; Servais EL; Tang LH; Sima CS; Gerdes H; Fleisher M; Rusch VW; Adusumilli PS
    Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):482-6. PubMed ID: 22237988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of circulating miR130a is correlated with development of Barrett's esophagus and esophageal adenocarcinoma.
    Wang L; Ji F; Liu G; Wang W; Li Z; Yue Y; Wang Z
    Onco Targets Ther; 2019; 12():1-7. PubMed ID: 30588024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of Esophageal Adenocarcinoma and Causes of Mortality After Radiofrequency Ablation of Barrett's Esophagus.
    Wolf WA; Pasricha S; Cotton C; Li N; Triadafilopoulos G; Muthusamy VR; Chmielewski GW; Corbett FS; Camara DS; Lightdale CJ; Wolfsen H; Chang KJ; Overholt BF; Pruitt RE; Ertan A; Komanduri S; Infantolino A; Rothstein RI; Shaheen NJ
    Gastroenterology; 2015 Dec; 149(7):1752-1761.e1. PubMed ID: 26327132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
    Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Notch signaling drives development of Barrett's metaplasia from Dclk1-positive epithelial tuft cells in the murine gastric mucosa.
    Kunze B; Middelhoff M; Maurer HC; Agibalova T; Anand A; Bührer AM; Fang HY; Baumeister T; Steiger K; Strangmann J; Schmid RM; Wang TC; Quante M
    Sci Rep; 2021 Feb; 11(1):4509. PubMed ID: 33627749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
    Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
    Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laryngopharyngeal reflux symptoms better predict the presence of esophageal adenocarcinoma than typical gastroesophageal reflux symptoms.
    Reavis KM; Morris CD; Gopal DV; Hunter JG; Jobe BA
    Ann Surg; 2004 Jun; 239(6):849-56; discussion 856-8. PubMed ID: 15166964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between endoscopic forceps biopsies and endoscopic mucosal resection with endoscopic ultrasound in patients with Barrett's esophagus with high-grade dysplasia and early cancer.
    Thota PN; Sada A; Sanaka MR; Jang S; Lopez R; Goldblum JR; Liu X; Dumot JA; Vargo J; Zuccarro G
    Surg Endosc; 2017 Mar; 31(3):1336-1341. PubMed ID: 27444824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
    Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
    Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.